"Factive" inducing foreign capital investment.

For the first time in Korea "Factive", a novel antibiotic agent originally developed by LGCI, has been approved by the U. S. FDA, indicating its high technology of Korea for the new drug manufacture and the sustained technology innovation in Korea, which eventually may contribute to more foreigner's capital investment to Korea for the new drug research and development.

After the implementati...